Eli Lilly’s (LLY) US prescriptions for Zepbound were 1,390 for the week ended April 10, according to IQVIA data

Eli Lilly's recent prescription figures for Zepbound indicate early interest in the product, but the 1,390 prescriptions reported may require context to evaluate their significance against broader expectations or past performance. If this aligns with or exceeds expectations, it could bode well for Eli Lilly’s revenue outlook in the pharmaceutical sector, while a shortfall may raise questions about the drug's market acceptance. Investors should monitor subsequent weeks' data for trend confirmation and potential impacts on stock performance.